Clinical trials: Exacerbation Copd
Pulmonary Disease, Chronic Obstructive
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD).
- Trial name
- VIGILANT (NCT07177339)
- Testing
- Depemokimab
- Where
- 121 sites in United States, Australia and 11 more
- Volunteers
- 1,196 people
- Sponsor
- GlaxoSmithKline
Respiratory Failure, Neuromuscular Disease
Ventilator Monitoring in Early Exacerbation Detection
The aim of this study is to determine whether respiratory disease exacerbations (a sudden worsening of symptoms) can be predicted by variables that are monitored by non-invasive ventilators (small machines that assist breathing)…
- Conditions
- Respiratory Failure, Neuromuscular Disease, Chest Wall Disorder, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT01644162
- Testing
- iVAPS ventilation
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- ResMed
Lung Diseases, Bronchitis, Chronic
Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis
Moxifloxacin, is being tested at approximately 60 study centres in 15 countries to determine if this drug, when taken periodically in addition to the patients normal treatment, is effective at reducing the number of flare-ups of…
- Trial name
- NCT00473460
- Testing
- Avelox (Moxifloxacin, BAY12-8039)
- Where
- 78 sites in United States, Andorra and 13 more
- Volunteers
- 1,404 people
- Sponsor
- Bayer
Chronic Obstructive Pulmonary Disease
Exacerbation Study
This study compares indacaterol with tiotropium in terms of bronchodilation over 52 weeks
- Trial name
- INVIGORATE (NCT00845728)
- Testing
- Indacaterol 150 µg, Tiotropium
- Where
- 423 sites in Argentina, Australia and 38 more
- Volunteers
- 3,439 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Effect of Remote Physiologic Monitoring (RPM) on Outcomes in COPD Patients
This pre/post study was a retrospective analysis of unplanned hospitalization rates in a cohort of COPD subjects started on remote physiologic monitoring (RPM) at a large, outpatient pulmonary practice.
- Trial name
- NCT05518981
- Testing
- Respiratory Remote Patient Monitor (Spire Health Tag)
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Spire, Inc.
Pulmonary Disease, Chronic Obstructive
Outcomes Associated With Early or Delayed Maintenance Treatment Post-Chronic Obstructive Pulmonary Disease Exacerbation
The timing of initiating short-term treatment for COPD exacerbations with oral corticosteroids and/or antibiotic therapy has been shown to influence the recovery time of exacerbations with early initiation of exacerbation therapy…
- Trial name
- NCT01431911
- Testing
- Early maintenance treatment, Delayed Maintenance treatment
- Volunteers
- 3,806 people
- Sponsor
- GlaxoSmithKline
COPD Exacerbation
Early Detection of COPD Exacerbations Using Home Monitoring Device
The goal of this observational study is to evaluate the safety and effectiveness of a home-monitoring device (RespirAI) in the early detection of COPD exacerbations in adults (age >21) with physician-diagnosed COPD who are at…
- Trial name
- NCT07554352
- Testing
- RespirAI
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- RespirAI US Inc
Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation
Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease
The purpose of this trial is to investigate if roflumilast can reduce the neutrophilic inflammation at acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- TREAT (NCT01473758)
- Testing
- Roflumilast
- Where
- 2 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- AstraZeneca
Asthma Acute, COPD Exacerbation Acute
Rademikibart IV for Acute Asthma and COPD Exacerbation
A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation
- Trial name
- NCT07705737
- Testing
- Rademikibart
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Connect Biopharm LLC
Pulmonary Disease, Chronic Obstructive
A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The study evaluates the efficacy of fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with…
- Trial name
- NCT02164513
- Testing
- fluticasone furoate (FF), vilanterol (VI), umeclidinium bromide (UMEC)
- Where
- 998 sites in United States, Argentina and 35 more
- Volunteers
- 10,355 people
- Sponsor
- GlaxoSmithKline
COPD
High Risk Populations Among COPD Patients in Japan
The patients with complications of COPD and asthma have features mixed with two diseases, COPD and asthma. Therefore, the outcomes are worsened if the patients with COPD have symptoms overlapped with asthma, however, no…
- Trial name
- NCT02413359
- Where
- Japan
- Volunteers
- 1,016 people
- Sponsor
- AstraZeneca
COPD
Boosting Regional Integration for COP D Care Through Guided Implementation and Audit of Post Exacerbation Transition Bundle
This is a cluster randomized interventional study. Intervention is implemented at a hospital level and will change overall daily practice.
- Trial name
- BRIDGE-COPD (NCT06646419)
- Where
- 37 sites in China
- Volunteers
- 1,368 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Comparison Between Symbicort® and Prednisolone in COPD
To assess if Symbicort forte Turbuhaler (during two weeks) is as effective as an oral course of prednisolone + Oxis Turbuhaler (during two weeks) for the treatment of an acute exacerbation of Chronic Obstructive Pulmonary Disease…
- Trial name
- SPACE (NCT00259779)
- Testing
- budesonide/formoterol, Prednisolone
- Where
- 37 sites in Denmark, Finland and 3 more
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Bronchitis, Chronic
Telithromycin: in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adult Outpatients With COPD
Non-inferiority efficacy of telithromycin versus azithromycin
- Trial name
- NCT00538148
- Testing
- Telithromycin
- Volunteers
- 668 people
- Sponsor
- Sanofi
COPD (Chronic Obstructive Pulmonary Disease)
The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD.
- Trial name
- STRIDE (NCT07612878)
- Testing
- Cohort 1: Dupilumab, Cohort 2: usual care only
- Where
- 7 sites in United States
- Volunteers
- 350 people
- Sponsor
- Sanofi
Pulmonary Disease, Chronic Obstructive
Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Nemiralisib is being developed as an anti-inflammatory drug for the treatment of inflammatory airways disease. This study is designed to assess the dose response, efficacy, safety, and pharmacokinetics of nemiralisib across a…
- Trial name
- NCT03345407
- Testing
- Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg
- Where
- 161 sites in United States, Argentina and 14 more
- Volunteers
- 943 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation
The purpose of this study is to evaluate specific alterations in immune cell mechanisms related to neutrophil function as detected by PI3Kdelta-dependent changes in messenger ribonucleic acid (mRNA) extracted from induced sputum…
- Trial name
- NCT02522299
- Testing
- GSK2269557, DISKUS, ELLIPTA
- Where
- 6 sites in Canada, Denmark
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Clinical Outcome of Corticosteroids in the Treatment of COPD Exacerbations in China
This is a Post-hoc analysis based on the database of "A non-interventional, retrospective study on AECOPD treatment status in China".
- Trial name
- CONTAIN (NCT03633838)
- Where
- China
- Volunteers
- 5,067 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
CareCOPD - COPD Home Monitoring Study
This is a pilot study to demonstrate early validation of objective home-monitoring of Chronic obstructive pulmonary disease (COPD) patients by combining accurate and relevant patient data of medication and lung function (lung…
- Trial name
- NCT04918095
- Testing
- CareCOPD Platform
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Cognita Labs LLC
Asthma, Copd
Inhaler Trainer Efficacy Study
This will be a randomized, controlled, clinical trial. The investigators aim to determine the feasibility of and efficacy of the Inhaler Trainer Device for ongoing inhaler skill training.
- Conditions
- Asthma, Copd, Acute Exacerbation of COPD
- Trial name
- NCT06461403
- Testing
- Inhaler Trainer System, Initial Inhaler Use Assessment, Inhaler Use Instruction
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Koronis Biomedical Technologies